HC Wainwright Predicts Editas Medicine Q1 Earnings

Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Stock analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Editas Medicine in a research report issued to clients and investors on Monday, April 28th. HC Wainwright analyst M. Kapoor expects that the company will post earnings of ($0.55) per share for the quarter. HC Wainwright has a "Strong-Buy" rating and a $3.00 price objective on the stock. The consensus estimate for Editas Medicine's current full-year earnings is ($2.71) per share. HC Wainwright also issued estimates for Editas Medicine's Q2 2025 earnings at ($0.33) EPS, Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($1.50) EPS, Q1 2026 earnings at ($0.45) EPS, Q2 2026 earnings at ($0.39) EPS, Q3 2026 earnings at ($0.48) EPS, Q4 2026 earnings at ($0.18) EPS and FY2026 earnings at ($1.49) EPS.

Editas Medicine (NASDAQ:EDIT - Get Free Report) last announced its quarterly earnings results on Wednesday, March 5th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.16). Editas Medicine had a negative return on equity of 80.13% and a negative net margin of 340.96%. The firm had revenue of $30.60 million for the quarter, compared to analyst estimates of $37.17 million. During the same quarter in the prior year, the company earned ($0.23) earnings per share.

Separately, Cantor Fitzgerald raised shares of Editas Medicine from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, April 29th. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating, three have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $6.54.

Editas Medicine Stock Up 1.2 %

Shares of Editas Medicine stock traded up $0.02 during trading hours on Thursday, hitting $1.64. The company's stock had a trading volume of 1,874,744 shares, compared to its average volume of 2,583,844. The business has a fifty day moving average of $1.42 and a 200 day moving average of $1.77. Editas Medicine has a 1-year low of $0.91 and a 1-year high of $6.69. The company has a market capitalization of $137.28 million, a PE ratio of -0.64 and a beta of 2.14.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in EDIT. Renaissance Technologies LLC bought a new stake in Editas Medicine in the fourth quarter valued at about $1,843,000. Balyasny Asset Management L.P. grew its position in shares of Editas Medicine by 647.3% in the 4th quarter. Balyasny Asset Management L.P. now owns 1,300,604 shares of the company's stock worth $1,652,000 after acquiring an additional 1,126,569 shares in the last quarter. Monaco Asset Management SAM bought a new stake in shares of Editas Medicine in the 4th quarter valued at approximately $1,359,000. Two Sigma Advisers LP raised its position in shares of Editas Medicine by 46.8% during the 4th quarter. Two Sigma Advisers LP now owns 1,657,000 shares of the company's stock valued at $2,104,000 after acquiring an additional 528,000 shares in the last quarter. Finally, Tang Capital Management LLC bought a new position in Editas Medicine during the fourth quarter worth $508,000. 71.90% of the stock is owned by institutional investors and hedge funds.

About Editas Medicine

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.